Lexeo Therapeutics (NASDAQ: LXEO) investors approve directors and ratify KPMG auditor
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Lexeo Therapeutics, Inc. reported results from its 2026 Annual Meeting of Stockholders held virtually on June 25, 2026. Stockholders elected three Class III directors—R. Nolan Townsend, Brenda Cooperstone, M.D., and Paula HJ Cholmondeley—to serve until the 2029 annual meeting.
Support for the director nominees ranged from 48,792,570 to 64,731,479 votes in favor, with broker non-votes of 9,955,777 on each director. Stockholders also ratified the appointment of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 75,497,386 votes for, 55,579 against, and 30,099 abstentions.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.07 — Submission of Matters to a Vote of Security Holders
1 item
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Key Figures
Votes for R. Nolan Townsend: 64,731,479 votes
Votes for Brenda Cooperstone, M.D.: 48,792,570 votes
Votes for Paula HJ Cholmondeley: 64,652,712 votes
+4 more
7 metrics
Votes for R. Nolan Townsend
64,731,479 votes
Election as Class III Director at 2026 annual meeting
Votes for Brenda Cooperstone, M.D.
48,792,570 votes
Election as Class III Director at 2026 annual meeting
Votes for Paula HJ Cholmondeley
64,652,712 votes
Election as Class III Director at 2026 annual meeting
Broker non-votes on director elections
9,955,777 votes
Each Class III Director proposal at 2026 annual meeting
Votes for KPMG ratification
75,497,386 votes
Ratification of independent auditor for fiscal year ending December 31, 2026
Votes against KPMG ratification
55,579 votes
Ratification of independent auditor at 2026 annual meeting
Abstentions on KPMG ratification
30,099 votes
Ratification of independent auditor at 2026 annual meeting
Key Terms
Annual Meeting of Stockholders, Class III Directors, broker non-vote, independent registered public accounting firm, +1 more
5 terms
Annual Meeting of Stockholders financial
"On June 25, 2026, Lexeo Therapeutics, Inc. held its virtual 2026 Annual Meeting of Stockholders"
Class III Directors financial
"The Company’s stockholders elected the persons listed below as Class III Directors"
Class III directors are members of a company’s board assigned to one of several staggered term groups, so only that class faces election in a particular year while other classes stay in place. For investors this affects corporate control and takeover risk because staggered elections make it slower and harder for an outside group to replace a majority of directors quickly—think of it as a rotating schedule for board seats that provides continuity but can also entrench existing leadership.
broker non-vote financial
"The final voting results are as follows | FOR | WITHHELD | BROKER NON-VOTE"
independent registered public accounting firm financial
"ratified the selection by the Audit Committee of KPMG LLP as the Company’s independent registered public accounting firm"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
Audit Committee financial
"ratified the selection by the Audit Committee of the Company’s Board of Directors of KPMG LLP"
A company's audit committee is a small group of board members who act like independent inspectors for the firm's finances, overseeing how financial reports are prepared, monitoring internal controls, and managing the relationship with external auditors. Investors care because a strong audit committee reduces the risk of accounting errors, fraud, or misleading statements, making financial statements more trustworthy and helping protect shareholder value.
FAQ
What did Lexeo Therapeutics (LXEO) stockholders approve at the 2026 annual meeting?
Stockholders elected three Class III directors and ratified KPMG LLP as independent auditor for 2026. The directors will serve until the 2029 annual meeting, and the strong “for” votes indicate broad support for both the board slate and the audit firm.
Who was elected as a Class III director of Lexeo Therapeutics (LXEO)?
R. Nolan Townsend, Brenda Cooperstone, M.D., and Paula HJ Cholmondeley were elected as Class III directors. They will serve until the 2029 Annual Meeting of Stockholders, continuing board oversight of Lexeo Therapeutics’ strategy and governance during this multi‑year term.
How many votes did Lexeo Therapeutics (LXEO) directors receive in favor?
Votes in favor were 64,731,479 for R. Nolan Townsend, 48,792,570 for Brenda Cooperstone, M.D., and 64,652,712 for Paula HJ Cholmondeley. Each director also had 9,955,777 broker non‑votes reported in the results table.
Did Lexeo Therapeutics (LXEO) stockholders ratify KPMG as auditor for 2026?
Yes. Stockholders ratified KPMG LLP as independent registered public accounting firm for the year ending December 31, 2026. The vote totals were 75,497,386 for, 55,579 against, and 30,099 abstentions, signaling strong backing for the company’s chosen auditor.
When was Lexeo Therapeutics’ 2026 Annual Meeting of Stockholders held?
The 2026 Annual Meeting of Stockholders was held on June 25, 2026, as a virtual meeting conducted via live webcast. During this meeting, stockholders voted on director elections and the ratification of KPMG LLP as the company’s independent auditor.